SELECTED STATEMENTS OF OPERATIONS DATA

12 Months Ended

Dec. 31, 2024

Disclosure Text Block Supplement [Abstract]

SELECTED STATEMENTS OF OPERATIONS DATA

NOTE 8:-          SELECTED STATEMENTS OF OPERATIONS DATA

a. Research and development expenses:

	Year ended December 31,
	2024		2023		2022
Subcontractors and consultants	$	793	$	1,001	$	2,228
Payroll and related expenses		543		699		766
Share-based compensation expense		80		73		285
Clinical trials expenses		10,289		4,262		1,121
Other expenses		-		-		22
	$	11,705	$	6,035	$	4,422

b. General and administrative expenses:

	Year ended December 31,
	2024		2023		2022
Professional services	$	1,390	$	1,209	$	1,489
Payroll and related expenses		815		877		780
D&O insurance		263		394		653
Rent and office maintenance		146		191		249
Share-based compensation expense		230		731		1,104
Other expenses		124		147		172
	$	2,968	$	3,549	$	4,447

c. Other financial income (expenses), net:

	Year ended December 31,
	2024			2023			2022
Interest income		101			406			160
Issuance expenses		-			(368	)		-
Bank fees		(14	)		(16	)		(13	)
Loss from Inducement offer letter agreement (Note 7c)		-			(1,502	)		-
Change in fair value of derivative warrant liability (Note7c)		-			1,726			-
Exchange rate differences	$	6			2		$	(61	)
Total other financial expenses, net	$	93			248		$	86